| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8714649 | The Journal of Allergy and Clinical Immunology: In Practice | 2017 | 8 Pages |
Abstract
Nearly all patients with severe sensitivity to rituximab can be successfully desensitized. IgE-mediated mechanism and mast cell degranulation, in addition to cytokine release syndrome and tumor lysis syndrome, may contribute to a significant portion of hypersensitivity reactions among patients with RITS.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Johnson T. MD, Aidan MD,